Expo Theater

Monday, October 14, 2019

Non-ticketed events. Limited seating for first 200 attendees.

10:05 am – 10:45 am

Ferring Pharmaceuticals, Inc.

No IUI, No IVF. Can There Still Be A Baby?

Amber Cooper MD, MSCI, FACOG
Meaghan Bowling, M.D., FACOG
Along With Their Patients

Featuring both physician and patient perspectives on how Intravaginal Culture (IVC) using INVOCELL provides an alternative fertility treatment. Join Ferring Pharmaceuticals to learn more about this innovative option.

3:30 pm – 4:10 pm

Agilent Technologies

Innovations in PGT Testing for Routine Assessment of Chromosomal Anomalies in the Clinic

Svetlana Yatsenko, M.D.
Director of the Pittsburgh Cytogenetics Laboratory, Associate Professor, Departments of Pathology, Obstetrics, Gynecology & Reproductive Sciences, and Human Genetics, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania

Agilent’s proven CGH and NGS solutions for human reproductive genetics deliver trusted answers to help you achieve superior outcomes for demanding clinical applications – now and for future applications.

Tuesday, October 15, 2019

Non-ticketed events. Limited seating for first 200 attendees.

10:05 am – 10:45 am


Transforming the Future of Reproductive Health through Genomics, Big Data, and Patient Engagement

Dr. Jamie Coffin
President & COO, Sema4


  • Dr. Jaime Shamonki, Chief Medical Officer, California Cryobank Life Sciences
  • Dr. Lisa Edelmann, Chief Diagnostics Officer, Sema4
  • Dr. Alan Copperman, Vice Chair of OB/GYN Dept at Mount Sinai Health System, and Chief Medical Officer, Sema4
  • August Calhoun, EVP and President, Sales & Operations, Change Healthcare

The panel will discuss key technology-driven trends transforming reproductive health to improve patient outcomes. These range from single-cell sequencing and its impact on preimplantation genetic testing (PGT), to the advent of personalized risk scores for expanded carrier screening using ancestry information from low pass whole genome sequencing, to earlier prediction of pregnancy complications using machine learning analysis of massive numbers of EMRs and patient engagement with digital tools for real-time monitoring.

12:20 pm – 1:00 pm

Includes complimentary boxed lunch


Beyond Carrier Screening: the Emerging Role of Preimplantation Genetic Testing (PGT) for Hereditary Cancer

Joe Leigh Simpson, M.D., FACOG, FACMG, FRCOG
Professor of Human & Molecular Genetics, Professor of Obstetrics and Gynecology, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida

Ethnicity-based carrier screening is rapidly being replaced by pan-ethnic screening. This increases considerably the number of at-risk couples who can benefit from preimplantation genetic testing (PGT) or prenatal genetic diagnosis. In addition, gene panels are now routine for individuals with cancer and other adult-onset heritable disorders, leading other family members to learn they are susceptible. Controversy surrounding PGT for adult-onset disorders has largely dissipated upon acceptance that varied expressivity exists for many conditions and age of onset differs among families. These advances have resulted in greater demand for genetic screening and testing, applicable to a broad population.